BPC 157's Cytoprotective Role in Arrhythmias Alongside Conventional Therapies
Conventional Antiarrhythmics Class I–IV, Late INa Inhibitors, IKs Enhancers, RyR2 Stabilizers, Gap Junction Modulators, Atrial-Selective Antiarrhythmics, and Stable Gastric Pentadecapeptide BPC 157 as
Background
Arrhythmias, or irregular heartbeats, are a significant cause of cardiovascular morbidity and mortality, often leading to serious complications like heart failure and sudden cardiac death. While conventional antiarrhythmics (Class I–IV) target specific ion channels to restore normal rhythm, they frequently come with side effects and may not fully address underlying cellular damage or long-term cardiac health. This comprehensive review explores the potential of BPC 157 as a cytoprotective agent to complement existing antiarrhythmic strategies by protecting heart cells from damage and promoting repair.